Eli Lilly and Co LLY Traded Lower in Q2 Despite Good Results
Published on August 12, 2025
Eli Lilly and Company, despite reporting good results in the second quarter of this year, saw its stock price traded lower. The pharmaceutical giant had a strong performance, with Mounjaro Zepbound sales soaring, but this did not seem to impress investors. As the company hiked its 2025 outlook and topped quarterly estimates, the market still reacted negatively. Analysts suggest that this dip may present a buying opportunity for those interested in investing in LLY stock.
Investor opinions & comments
To leave a comment, you need to Login or Register.
SaraBrown
August 15, 2025 at 14:15
I'm not convinced that the good results from Eli Lilly in Q2 will necessarily lead to a long-term positive trend. The market reaction seems to be a red flag
BudgetBobby
August 14, 2025 at 12:33
I think this dip in Eli Lilly's stock price might be a good buying opportunity. Their strong performance and positive outlook for 2025 show a promising future
MatthewGarcia
August 14, 2025 at 00:54
I'm hesitant to jump into investing in Eli Lilly's stock, despite the positive results. The market's reaction might be signaling underlying concerns
CashMike
August 13, 2025 at 23:21
I'm intrigued by Eli Lilly's performance in Q2 despite the stock price decline. It could be worth looking into for potential investment
JoshuaAdams
August 12, 2025 at 22:19
I'm skeptical about the future prospects of Eli Lilly's stock given the market's negative reaction to their good results in Q2
WealthyMary
August 12, 2025 at 10:33
I'm interested in seeing how Eli Lilly's stock price will rebound after the second quarter results. Their growth with Mounjaro Zepbound sales is impressive